Enhancing the Therapeutic Efficacy of Anticancer Agents Through Strategic Chemical Modification and Targeted Conjugation

Despite decades of breakthroughs in oncology, the clinical efficacy of many anticancer drugs remains constrained by limited tumor selectivity, systemic toxicity, poor pharmacokinetics, and the development of multidrug resistance. These limitations not only reduce therapeutic efficacy but also adversely affect patient well-being, underscoring an urgent need for more intelligent and targeted therapeutic strategies to enhance treatment outcomes. Instead of relying solely on the discovery of new therapeutic compounds, a promising strategy has emerged through selective chemical modification and targeted conjugation of current anticancer agents. Chemical modification approaches, such as prodrug design, bioisosteric replacement, stereochemical refinement, and molecular scaffold engineering, provide an accurate modulation of drug solubility, stability, permeability, and metabolic trajectory. These actions can prolong drug half-life, enhance tumor penetration, and reduce dose-limiting toxicities. Alongside these methods, conjugation strategies involving antibodies, peptides, aptamers, or polymeric carriers enable the targeted delivery of cytotoxic drugs to malignant cells, thereby preserving healthy tissues intact. The efficacy of antibody–drug conjugates and the expanding array of small-molecule and polymer–drug conjugates offer a persuasive proof that chemical modification can convert conventional chemotherapeutics into advanced precision therapies. Beyond delivery, incorporation of stimuli-responsive linkers and tumor microenvironment-sensitive release mechanisms enhances spatiotemporal control, confirming that drugs are activated only under pathological environments like acidic pH or redox imbalance. These tactics improve efficacy while minimizing undesirable consequences, thereby integrating treatment action more closely with the complex biology of cancer. This chapter elucidates the principles, methodologies, and translational prospects of increasing anticancer drug efficacy via chemical modification and conjugation. Moreover, it highlights the importance of molecular advances in transforming cancer therapies by integrating fundamental chemistry concepts with advancements in clinical oncology. The main objective is to exhibit rational and strategic drug design, thereby facilitating the development of effective interventions and enhancing safety, precision, and alignment with patient-specific clinical needs.